OVA1®plus is a reflex process which first performs OVA1® and then performs OVERA® if the OVA1® result is in the intermediate range. OVA1®plus has the potential to help you further stratify your patient’s risk of malignancy.
Low Risk is <4.4 (Postmenopausal) and <5.0 (Premenopausal) Intermediate Risk is 4.4-6.0 (Postmenopausal) and 5.0-7.0 (Premenopausal) Markedly Elevated Risk is >6.0 (Postmenopausal) and >7.0 (Premenopausal)
What are the benefits of OVA1®plus?
The combination of OVA1 and OVERA can help you further stratify your patient’s risk of malignancy.
Research Supported Improved Early Stage Detection: OVA1®plus vs
CA-125II in Stage I + II Patients*
Biomarkers in OVA1 & OVERA
- Bristow RE, Smith A, Zhange Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013; 128: 252-259.